Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

Department of Pediatrics, Sloan-Kettering Institute, New York, NY 10065, USA.
The Journal of clinical investigation (Impact Factor: 13.77). 08/2012; 122(9):3260-70. DOI: 10.1172/JCI62749
Source: PubMed

ABSTRACT Survival outcomes for patients with high-risk neuroblastoma (NB) have significantly improved with anti-disialoganglioside GD2 mAb therapy, which promotes NK cell activation through antibody-dependent cell-mediated cytotoxicity. NK cell activation requires an interaction between inhibitory killer cell immunoglobulin-like receptors (KIRs) and HLA class I ligands. NK cells lacking KIRs that are specific for self HLA are therefore "unlicensed" and hyporesponsive. mAb-treated NB patients lacking HLA class I ligands for their inhibitory KIRs have significantly higher survival rates, suggesting that NK cells expressing KIRs for non-self HLA are mediating tumor control in these individuals. We found that, in the presence of mAb, both licensed and unlicensed NK cells are highly activated in vitro. However, HLA class I expression on NB cell lines selectively inhibited licensed NK cell activity, permitting primarily unlicensed NK cells to mediate antibody-dependent cell-mediated cytotoxicity. These results indicate that unlicensed NK cells play a key antitumor role in patients undergoing mAb therapy via antibody-dependent cell-mediated cytotoxicity, thus explaining the potent "missing KIR ligand" benefit in patients with NB.

Download full-text


Available from: Nidale Tarek, May 05, 2015
  • Source
    • "Even though these studies demonstrated an important role for KIR and KIR-HLA interactions in various diseases, the underlying mechanisms are only beginning to be understood (Anfossi et al., 2006; Alter et al., 2007, 2009; Ahlenstiel et al., 2008; Hiby et al., 2010; O'Connor et al., 2011; Tarek et al., 2012). A critical gap in our knowledge is the fact that ligands for many activating, and some inhibitory, KIR are unknown. "
    Frontiers in Immunology 12/2012; 3:394. DOI:10.3389/fimmu.2012.00394
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is a wide range of important pharmaceuticals used in treatment of cancer. Besides their known effects on tumor cells, there is growing evidence for modulation of the immune system. Immunomodulatory drugs (IMiDs(®)) play an important role in the treatment of patients with multiple myeloma or myelodysplastic syndrome and have already demonstrated antitumor, anti-angiogenic, and immunostimulating effects, in particular on natural killer (NK) cells. Tyrosine kinase inhibitors are directly targeting different kinases and are known to regulate effector NK cells and expression of NKG2D ligands (NKG2DLs) on tumor cells. Demethylating agents, histone deacetylases, and proteasome inhibitors interfere with the epigenetic regulation and protein degradation of malignant cells. There are first hints that these drugs also sensitize tumor cells to chemotherapy, radiation, and NK cell-mediated cytotoxicity by enhanced expression of TRAIL and NKG2DLs. However, these pharmaceuticals may also impair NK cell function in a dose- and time-dependent manner. In summary, this review provides an update on the effects of different novel molecules on the immune system focusing NK cells.
    Frontiers in Immunology 01/2012; 3:388. DOI:10.3389/fimmu.2012.00388
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cells of the immune system have evolved various molecular mechanisms to sense their environment and react to alterations of self. NK cells are lymphocytes with effector and regulatory functions, which are remarkably adaptable to changes in self. In a study published in this issue of the JCI, Tarek and colleagues report the clinical benefits of manipulating NK cell adaptation to self in an innovative mAb-based therapy against neuroblastoma (NB). This novel therapeutic strategy should stimulate further research on NK cell therapies.
    The Journal of clinical investigation 08/2012; 122(9):3053-6. DOI:10.1172/JCI63524 · 13.77 Impact Factor
Show more